Table 1.
Clinical characteristics of patients with nosocomial pneumonia caused by different Pseudomonas aerugionsa serotypes (n = 123)
| Serotypes | All | O1 | O2 | O6 | O10 | O11 | PL5 | NT |
|---|---|---|---|---|---|---|---|---|
| VAP/NP, n (%) | 114/123 (93) | 9/10 (90) | 10/11 (91) | 35/36 (92) | 10/12 (83) | 26/28 (93) | 15/16 (94) | 9/10 (90) |
| Age, years | 61 (43 to 72) | 65 (56 to 74) | 63 (58 to 70) | 57 (39 to 67) | 59 (40 to 77) | 65 (42 to 78) | 64 (47 to 71) | 64 (59 to 72) |
| Male% | 75 | 40 | 73 | 81 | 92 | 68 | 81 | 80 |
| Antibiotics at pneumonia onset, n, % | 84 (68) | 5 (50) | 8 (73) | 28 (78) | 12 (100) | 13 (46) | 12 (75) | 6 (60) |
| Inappropriately treated % | 11 | 0 | 0 | 14 | 8 | 14 | 6 | 0 |
| MCPIS | 7.0 (5.0 to 9.0) | 8.0 (5.8 to 9.5) | 9.0 7 to 10) | 7 (5 to 8) | 6 (4 to 8) | 8.5 (7 to 9.5) | 7.5 5 to 9) | 6.0 (4 to 8) |
| APACHE II score | 17 (12 to 22) | 17 (11 to 29) | 15 (11 to 17) | 17 (11to 23) | 17 (11 to 29) | 17 (14 to 20) | 19 (12 to 26) | 16 (12 to 19) |
| SOFA score | 7.0 (5.0 to10.0) | 9.5 (6.5 to 15.0) | 5 (4 to 7) | 7 (5 to 10) | 9.5 (6.5 to 15.0) | 6.0 (4.5 to 8.0) | 7 (6.0 to 9.0) | 6.0 (4.0 to 9.2) |
| Hospital length of stay at inclusion, days | 13 (7 to 14) | 14 (8 to 45) | 8 (4 to 18) | 12 (7 to 25) | 13 (8 to 19) | 18 (8 to 34) | 12 (6 to 24) | 14 (8 to 25) |
| ICU length of stay at inclusion, days | 8 (4 to 17) | 11 (4 to 17) | 5 (3 to 12) | 7 (5 to 19) | 8 (3 to 13) | 9 (6 to 19) | 8 (4 to 15) | 9 (5 to 14) |
| Duration of mechanical ventilation at inclusion, days | 8 (5 to 17) | 10.5 (7 to 17) | 5 (3 to 12) | 8 (5 to18) | 9 (4 to 13) | 9 (5 to 17) | 8 (4 to 15) | 9 (6 to 14) |
Data are expressed as median and 25%-75% interquartile. Nosocomial pneumonia (NP) includes hospital-acquired pneumonia and ventilator-associated pneumonia (VAP). APACHE II, Acute Physiology and Chronic Health Evaluation II; ICU, intensive care unit; MCPIS, modified clinical pulmonary infection score; NT, not typeable; PL5, sum of all serotypes with a prevalence of less than 5%; SOFA, sequential organ failure assessment.